Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2024

Open Access 01-12-2024 | Phlebothrombosis | Research

Prevalence, risk factors, and clinical characteristics of pulmonary embolism in patients with acute exacerbation of COPD in Plateau regions: a prospective cohort study

Authors: Chenlu Yang, Yajun Tuo, Xuefeng Shi, Jie Duo, Xin Liu, Fang Zhang, Xiaokai Feng

Published in: BMC Pulmonary Medicine | Issue 1/2024

Login to get access

Abstract

Background and objective

To investigate pulmonary thromboembolism (PE) in acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) patients in plateau regions, we performed a prospective cohort study to evaluate the prevalence, risk factors and clinical characteristics of PE in the cohort of hospitalized patients at high altitude.

Methods

We did a prospective study with a total of 636 AE-COPD patients in plateau regions. Demographic and clinical data, laboratory data, including ultrasound scans of the lower extremities and cardiac ultrasound, and computed tomographic pulmonary angiography (CTPA) variables were obtained, and comparisons were made between groups with and without PE. We also conducted logistic regression to explore the risk factors of PE.

Results

Of the 636 patients hospitalized with AE-COPD (age 67.0 ± 10.7 years, 445[70.0%] male), 188 patients developed PE (29.6% [95% CI: 26.0%, 33.1%]). Multivariable logistic regression showed that ethnic minorities, D-dimer > 1 mg/L, AST > 40 U/L, chest pain, cardiac insufficiency or respiratory failure, Padua score > 3, and DVT were associated with a higher probability of PE.

Conclusions

The prevalence of PE is high and those with a higher Padua score, the occurrence of deep venous thrombosis, higher neutrophil count, chest pain, cardiac insufficiency or respiratory failure, higher levels of AST, and a higher level of D-dimer had a higher risk of PE. The analysis of AE-COPD may help to provide more accurate screening for PE and improve clinical outcomes of patients with AE-COPD in plateau regions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Global regional. and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Respiratory medicine. Sep 2017;5(9):691–706. https://doi.org/10.1016/s2213-2600(17)30293-x. Global regional. and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Respiratory medicine. Sep 2017;5(9):691–706. https://​doi.​org/​10.​1016/​s2213-2600(17)30293-x.
8.
go back to reference Białas AJ, Kornicki K, Ciebiada M, et al. Monocyte to large platelet ratio as a diagnostic tool for pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Polish archives of internal medicine. Jan. 2018;31(1):15–23. https://doi.org/10.20452/pamw.4141.CrossRef Białas AJ, Kornicki K, Ciebiada M, et al. Monocyte to large platelet ratio as a diagnostic tool for pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Polish archives of internal medicine. Jan. 2018;31(1):15–23. https://​doi.​org/​10.​20452/​pamw.​4141.CrossRef
11.
go back to reference Lippi G, Franchini M, Guidi GC. Dec. Prohibition of artificial hypoxic environments in sports: health risks rather than ethics. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2007;32(6):1206-7; discussion 1208-9. https://doi.org/10.1139/h07-088. Lippi G, Franchini M, Guidi GC. Dec. Prohibition of artificial hypoxic environments in sports: health risks rather than ethics. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2007;32(6):1206-7; discussion 1208-9. https://​doi.​org/​10.​1139/​h07-088.
13.
go back to reference Anand AC, Jha SK, Saha A, Sharma V, Adya CM. Thrombosis as a complication of extended stay at high altitude. Natl Med J India Jul-Aug. 2001;14(4):197–201. Anand AC, Jha SK, Saha A, Sharma V, Adya CM. Thrombosis as a complication of extended stay at high altitude. Natl Med J India Jul-Aug. 2001;14(4):197–201.
14.
go back to reference Ashraf HM, Javed A, Ashraf S. Pulmonary embolism at high altitude and hyperhomocysteinemia. J Coll Physicians Surgeons–Pakistan: JCPSP Jan. 2006;16(1):71–3. Ashraf HM, Javed A, Ashraf S. Pulmonary embolism at high altitude and hyperhomocysteinemia. J Coll Physicians Surgeons–Pakistan: JCPSP Jan. 2006;16(1):71–3.
15.
go back to reference Anand AC, Saha A, Kumar R, Sharma V, Jha SK. Portal system thrombosis: a new dimension of high altitude illnesses. Trop Gastroenterol: Official J Dig Dis Foundation Oct-Dec. 2000;21(4):172–3. Anand AC, Saha A, Kumar R, Sharma V, Jha SK. Portal system thrombosis: a new dimension of high altitude illnesses. Trop Gastroenterol: Official J Dig Dis Foundation Oct-Dec. 2000;21(4):172–3.
19.
go back to reference Yanamandra U, Boddu R, Pramanik S, et al. Prevalence and clinical characteristics of Post-thrombotic Syndrome in High-Altitude-Induced Deep Vein thrombosis: experience of a single Tertiary Care Center from Real-World Settings. High Altitude Med Biology Dec. 2020;21(4):319–26. https://doi.org/10.1089/ham.2020.0053.CrossRef Yanamandra U, Boddu R, Pramanik S, et al. Prevalence and clinical characteristics of Post-thrombotic Syndrome in High-Altitude-Induced Deep Vein thrombosis: experience of a single Tertiary Care Center from Real-World Settings. High Altitude Med Biology Dec. 2020;21(4):319–26. https://​doi.​org/​10.​1089/​ham.​2020.​0053.CrossRef
21.
go back to reference Smallman DP, McBratney CM, Olsen CH, Slogic KM, Henderson CJ. Feb. Quantification of the 5-year incidence of thromboembolic events in U.S. Air Force Academy cadets in comparison to the U.S. Naval and Military Academies. Military medicine. 2011;176(2):209–13. https://doi.org/10.7205/milmed-d-10-00144. Smallman DP, McBratney CM, Olsen CH, Slogic KM, Henderson CJ. Feb. Quantification of the 5-year incidence of thromboembolic events in U.S. Air Force Academy cadets in comparison to the U.S. Naval and Military Academies. Military medicine. 2011;176(2):209–13. https://​doi.​org/​10.​7205/​milmed-d-10-00144.
22.
go back to reference Halpin DMG, Criner GJ, Papi A, Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. Jan 1. Global Initiative for the Diagnosis, Management, and. 2021;203(1):24–36. https://doi.org/10.1164/rccm.202009-3533SO. Halpin DMG, Criner GJ, Papi A, Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. Jan 1. Global Initiative for the Diagnosis, Management, and. 2021;203(1):24–36. https://​doi.​org/​10.​1164/​rccm.​202009-3533SO.
Metadata
Title
Prevalence, risk factors, and clinical characteristics of pulmonary embolism in patients with acute exacerbation of COPD in Plateau regions: a prospective cohort study
Authors
Chenlu Yang
Yajun Tuo
Xuefeng Shi
Jie Duo
Xin Liu
Fang Zhang
Xiaokai Feng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-024-02915-z

Other articles of this Issue 1/2024

BMC Pulmonary Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine